2022
DOI: 10.21873/invivo.12766
|View full text |Cite
|
Sign up to set email alerts
|

Established Serum Biomarkers Are Prognostic Factors in Patients With Oligometastatic Cancer and Brain Involvement

Abstract: Background/Aim: This study was designed to evaluate the prognostic impact of the previously validated LabBM score (serum lactate dehydrogenase, C-reactive protein, albumin, hemoglobin, platelets) in a new setting, namely patients with a limited number of brain metastases, arbitrarily defined as max. 4 brain lesions, from common tumor types such as lung and breast cancer. A total of 5 metastatic lesions overall were allowed to comply with current definitions of oligometastatic cancer. Patients and Methods: Fo… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
4
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
4

Relationship

1
3

Authors

Journals

citations
Cited by 4 publications
(4 citation statements)
references
References 24 publications
0
4
0
Order By: Relevance
“…Promising results were seen in a recent study of 101 patients with maximum 4 brain metastases and 5 metastases in total, with respect to the fact that those with LabBM score 0 had an actuarial 5-year survival rate of 27% after neurosurgical resection and 39% after stereotactic radiotherapy ( 18 ). Utilization of the score, or blood biomarkers in a broader sense, renders comprehensive radiological re-staging unnecessary and is a low-cost intervention.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Promising results were seen in a recent study of 101 patients with maximum 4 brain metastases and 5 metastases in total, with respect to the fact that those with LabBM score 0 had an actuarial 5-year survival rate of 27% after neurosurgical resection and 39% after stereotactic radiotherapy ( 18 ). Utilization of the score, or blood biomarkers in a broader sense, renders comprehensive radiological re-staging unnecessary and is a low-cost intervention.…”
Section: Discussionmentioning
confidence: 99%
“…A recent retrospective study of 101 patients with maximum 4 brain metastases and 5 metastases in total (21% had limited extracranial metastases) showed that 49% had normal blood test results (LabBM score 0 points) ( 18 ). These patients’ median survival of 23 months was significantly longer than that of patients with higher LabBM score.…”
Section: Published Studies Leading To the Hypothesismentioning
confidence: 99%
“…Serum lactate dehydrogenase was analyzed by Nieder and colleagues in patients with oligometastatic brain metastases [68] and found to be associated with survival, because this biomarker may reflect the total burden of malignant disease. The same group validated a LabBM score (serum lactate dehydrogenase, C-reactive protein, albumin, hemoglobin, platelets) in patients with a limited number of brain metastases [69]. In another study of 403 oligometastatic patients that received SBRT, the prognostic value of the modified Glasgow Prognostic Score (mGPS) and the neutrophil-lymphocyte ratio (NLR) were investigated.…”
Section: Biomarkers In Oligometastatic Diseasementioning
confidence: 99%
“…The expression of certain circulating biomolecules is modified when a disease is established, having a great potential to detect and predict the disease as well as to identify the response to different treatments (3)(4)(5). For CC, there are several studies showing biomolecules, proteins, non-coding RNAs (ncRNAs), and circulating DNA (cDNA) with a great potential to be useful biomarkers for diagnosis, prognosis, and to determine the response to treatments currently used in medical attention for CC.…”
Section: Introductionmentioning
confidence: 99%